TNF and aplastic anemia: Although anti-TNF-α based therapy has been clinically successful, several notable caveats including an elevated risk of opportunistic infection, the induction of auto-Abs, injection-site and infusion reactions, and the exacerbation of previously quiescent conditions (such as multiple sclerosis or aplastic anemia) have been reported [24].